These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 1391037)
21. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C; Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070 [TBL] [Abstract][Full Text] [Related]
22. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2]. Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896 [TBL] [Abstract][Full Text] [Related]
23. Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies. Itoh K; Balch CM; Murray JL; Parkinson DR; Markowitz AB; Talpaz M; Lee K; Zukiwski AA; Ross MI; Legha SS In Vivo; 1991; 5(6):647-53. PubMed ID: 1810451 [TBL] [Abstract][Full Text] [Related]
24. Re: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. Legha SS J Natl Cancer Inst; 1995 Feb; 87(4):319. PubMed ID: 7707427 [No Abstract] [Full Text] [Related]
25. Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2. Nakamura Y; Wakimoto H; Abe J; Kanegae Y; Saito I; Aoyagi M; Hirakawa K; Hamada H Cancer Res; 1994 Nov; 54(22):5757-60. PubMed ID: 7525049 [TBL] [Abstract][Full Text] [Related]
26. [Adoptive immunotherapy of malignant pleural effusion with TIL/rIL2 (tumor-infiltrating lymphocytes/recombinant interleukin 2)]. Han B; Jia Y; Zhou M Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):91-3, 128. PubMed ID: 7553959 [TBL] [Abstract][Full Text] [Related]
27. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy. Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410 [TBL] [Abstract][Full Text] [Related]
28. [Combination of adoptive immunotherapy and chemotherapy against advanced cancer with peritoneal dissemination]. Iwahashi M; Tanimura H; Yamaue H; Tsunoda T; Tani M; Tamai M; Taniguchi K; Aoki Y Nihon Gan Chiryo Gakkai Shi; 1990 Aug; 25(8):1558-64. PubMed ID: 2172423 [TBL] [Abstract][Full Text] [Related]
29. Immunotherapy with the use of tumor-infiltrating lymphocytes and interleukin-2 as adjuvant treatment in stage III non-small-cell lung cancer. A pilot study. Ratto GB; Melioli G; Zino P; Mereu C; Mirabelli S; Fantino G; Ponte M; Minuti P; Verna A; Noceti P J Thorac Cardiovasc Surg; 1995 Jun; 109(6):1212-7. PubMed ID: 7776685 [TBL] [Abstract][Full Text] [Related]
31. Intratumoral adoptive immunotherapy with tumor infiltrating lymphocytes (TIL) in a melanoma patient leading to regression of local tumor mass. A case report. Möller P; Wittig B; Schadendorf D Anticancer Res; 1998; 18(2B):1237-41. PubMed ID: 9615794 [TBL] [Abstract][Full Text] [Related]
32. [Interleukin-2 and adoptive immunotherapy: their biological aspects and clinical application in oncology]. Barón Saura JM; Pizarro Redondo A; Berrocal Jaime A; González Barón M Rev Clin Esp; 1991 May; 188(9):468-72. PubMed ID: 1896596 [TBL] [Abstract][Full Text] [Related]
33. Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience. Semino C; Martini L; Queirolo P; Cangemi G; Costa R; Alloisio A; Ferlazzo G; Sertoli MR; Reali UM; Ratto GB; Melioli G Anticancer Res; 1999; 19(6C):5645-9. PubMed ID: 10697634 [TBL] [Abstract][Full Text] [Related]
35. A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy. Lange JR; Raubitschek AA; Pockaj BA; Spencer WF; Lotze MT; Topalian SL; Yang JC; Rosenberg SA J Immunother (1991); 1992 Nov; 12(4):265-71. PubMed ID: 1477077 [TBL] [Abstract][Full Text] [Related]
36. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. Rosenberg SA; Packard BS; Aebersold PM; Solomon D; Topalian SL; Toy ST; Simon P; Lotze MT; Yang JC; Seipp CA N Engl J Med; 1988 Dec; 319(25):1676-80. PubMed ID: 3264384 [TBL] [Abstract][Full Text] [Related]
37. [Application of gene therapy in tumor adoptive immunotherapy]. Wang C; Zhao Y Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Apr; 25(2):482-6. PubMed ID: 18610648 [TBL] [Abstract][Full Text] [Related]
38. [Treatment with autologous tumor-infiltrating lymphocytes and recombinant interleukin-2 in patients with lung carcinoma]. Li D; Zhang X; Song Y Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):152-5. PubMed ID: 7656811 [TBL] [Abstract][Full Text] [Related]
39. Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas. Silva IPD; Batten M; Long GV Br J Cancer; 2018 Sep; 119(6):661-662. PubMed ID: 30131552 [No Abstract] [Full Text] [Related]
40. Is antigen specificity the key to efficient adoptive T-cell therapy? Labarriere N; Khammari A; Lang F; Dreno B Immunotherapy; 2011 Apr; 3(4):495-505. PubMed ID: 21463191 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]